Argatroban

• CAT Number: I004778
• CAS Number: 74863-84-6
• Molecular Formula: C23H36N6O5S
• Molecular Weight: 508.6
• Purity: ≥95%
• Target: Thrombin
• Solubility: DMSO 9 mg/mL; Water <1 mg/mL
• Storage: 3 years -20℃ powder
• IUPAC Name: (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid
• InChI: InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15?,17+,18-/m1/s1
• InChIKey: KXNPVXPOPUZYGB-IOVMHBDKSA-N
• SMILES: CC1CC2=C(C(S(N[C@@H](CCCNC(N)=N)C(N3[C@@H](C(O)=O)C[C@H](C)CC3)=O)(=O)=O)=CC=C2)NC1

Argatroban (Cat.No:I004778) is a small molecule anticoagulant that inhibits thrombin by binding to its active site. It is used to prevent thrombosis in patients with heparin-induced thrombocytopenia (HIT) and as an anticoagulant during percutaneous coronary interventions. Argatroban is available in injectable formulations and is typically administered intravenously.

Reference

1:Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke). Barreto AD, Ford GA, Shen L, Pedroza C, Tyson J, Cai C, Rahbar MH, Grotta JC; ARTSS-2 Investigators..Stroke. 2017 May 15. pii: STROKEAHA.117.016720. doi: 10.1161/STROKEAHA.117.016720. [Epub ahead of print] PMID: 28507269 2:Use of an argatroban-based purge solution in a percutaneous ventricular assist device. Laliberte B, Reed BN.Am J Health Syst Pharm. 2017 May 1;74(9):e163-e169. doi: 10.2146/ajhp160212. PMID: 28438820 3:Early initiation of argatroban therapy in the management of acute superior mesenteric venous thrombosis. Zeng Q, Fu QN, Li FH, Wang XH, Liu H, Zhao Y.Exp Ther Med. 2017 Apr;13(4):1526-1534. doi: 10.3892/etm.2017.4103. Epub 2017 Feb 7. PMID: 28413504 Free PMC Article4:Local Intraluminal Irrigation With Argatroban During Free Flap Repair in a Patient With Heparin-Induced Thrombocytopenia. Macias D, Kwon DI, Walker PC, Peterson NR.Ann Otol Rhinol Laryngol. 2017 May;126(5):407-410. doi: 10.1177/0003489417693015. Epub 2017 Mar 1. PMID: 28397565 5:Monitoring of Argatroban and Lepirudin. Seidel H, Kolde HJ.Clin Appl Thromb Hemost. 2017 Jan 1:1076029617699087. doi: 10.1177/1076029617699087. [Epub ahead of print] PMID: 28320219 6:Heparin-induced thrombocytopenia with aortoiliac thrombosis treated with argatroban. Alarcón Pérez L, Rodríguez Huerta AM, Duque González P.Med Clin (Barc). 2017 Mar 22;148(6):286-287. doi: 10.1016/j.medcli.2016.12.019. Epub 2017 Jan 26. English, Spanish. No abstract available. PMID: 28131516 7:ISMP Medication Error Report Analysis: Aggrastat-Argatroban Mix-ups Don/’t Expect Radiofrequency Identification Stock Systems To Be Perfect Paralyzed by Mistakes: Reassess the Safety of Neuromuscular Blockers in Your Facility. Cohen MR, Smetzer JL.Hosp Pharm. 2016 Dec;51(11):877-883. doi: 10.1310/hpj5111-877. PMID: 28057945 8:Biodegradable polymer-based, argatroban-eluting, cobalt-chromium stent (JF-04) for treatment of native coronary lesions: final results of the first-in-man study and lessons learned. Morino Y, Tobaru T, Yasuda S, Kataoka K, Tanabe K, Hirohata A, Kozuma K, Kimura T.EuroIntervention. 2016 Nov 20;12(10):1271-1278. doi: 10.4244/EIJV12I10A208. PMID: 27866136 Free Article9:Further evidence of the limitations of Activated Partial Thromboplastin Time to monitor Argatroban. Guy S, Kitchen S, Van Veen JJ.Br J Haematol. 2016 Oct 26. doi: 10.1111/bjh.14397. [Epub ahead of print] No abstract available. PMID: 27785784 10:Monitoring anticoagulation with argatroban in critically ill patients: activated partial thromboplastin time versus diluted thrombin time. Keyl C, Lehane C, Zimmer E, Trenk D.Thromb Haemost. 2016 Nov 30;116(6):1180-1181. Epub 2016 Sep 15. No abstract available. PMID: 27628460